摘要
目的 观察索磷布韦联合利巴韦林治疗丙型病毒性肝炎(简称丙肝)的早期疗效及安全性。方法 选取2018年2—7月就诊的21例慢性丙肝患者作为研究对象,均采用索磷布韦联合利巴韦林的治疗方案。观察患者血清HCV RNA水平、肝功能指标(ALT、AST、TBIL)水平变化及治疗期间出现的不良反应,并分析索磷布韦合并其他用药的安全性。结果 治疗4周后,所有患者HCV RNA水平低于检测值下限;14例(66.7%)患者肝功能指标恢复到正常范围,7例(33.3%)为轻度异常。持续治疗12周后,HCV RNA水平仍低于检测值下限;18例(85.7%)患者肝功能指标恢复到正常范围,3例(14.3%)为轻度异常。治疗期间的不良反应主要为贫血,其他为全身乏力、失眠、头晕、腿部疼痛和胃肠道反应等。3例合并其他用药的患者中,未发现特殊不良反应的发生。结论 索磷布韦联合利巴韦林用于丙肝的治疗,早期疗效确切,安全性高。
Objective To observe the early efficacy and safety of sofosbuvir combined with ribavirin in the treatment of hepatitis C.Methods Twenty-one patients with hepatitis C virus(HCV) infection were treated with sofosbuvir and ribavirin in our hospital from February 2018 to July 2018.Changes in serum levels of HCV RNA,alanine transaminase(ALT),aspartate aminotransferase(AST) and total bilirubin(TBIL) and adverse reactions were observed,and the safety of medication was analyzed.Results After 4-week treatment,the levels of HCV RNA were below the detection limit in all patients,the indices of liver function returned to normal levels in 14 patients(66.7%),and mild hepatic dysfunction was observed in 7 patients(33.3%).After treatment for 12 weeks,HCV RNA levels were still below the detection limit in all patients,the indices of liver function returned to normal levels in 18 patients(85.7%),and mild hepatic dysfunction occurred in 3 patients(14.3%).During treatment,the main adverse reactions included anemia,systemic fatigue,insomnia,dizziness,leg pain and gastrointestinal response.No special adverse reactions were found in the 3 patients who also received other drugs.Conclusion Sofosbuvir combined with ribavirin is effective and safe for hepatitis C.
作者
朱滢
向天新
胡大利
石白茹
李忠敏
邬小萍
ZHU Ying;XIANG Tian-xin;HU Da-li;SHI Bai-ru;LI Zhong-min;WU Xiao-ping(Department of Infectious Diseases,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China)
出处
《南昌大学学报（医学版）》
CAS
2019年第3期64-67,共4页
Journal of Nanchang University：Medical Sciences
